Cancer is driven by dynamic molecular programs that evolve across disease stages and in response to therapeutic intervention. While genomic data reveals mutational potential, it does not fully capture how tumors function, adapt, or respond to treatment in patients.
Sapient’s multi‑omics tumor profiling services enable oncology teams to directly measure the proteins, metabolites, lipids, and immune signals that reflect active tumor biology. By integrating these orthogonal molecular layers with clinical context, we help you uncover actionable targets, develop robust biomarkers, and stratify patients with greater confidence across discovery, translational, and clinical development.
Which pathways are functionally active in my tumor samples?
What targets are both actionable and biologically relevant in human tumors?
How do tumors metabolically and immunologically adapt to therapy?
Which molecular features best predict response, resistance, or progression?
Rapidly identify disease‑modifying, druggable targets – including on the tumor surface proteome – with broad, direct measure of proteins and pathway activity across >10,000 proteins per tumor sample.
Discover biomarkers linked to tumor biology, therapeutic response, and resistance using integrated proteomic, metabolomic, lipidomic, and/or cytokine data to complement genomic insights.
Uncover biologically meaningful tumor subtypes by integrating molecular profiles with clinical and phenotypic features – for stratification rooted in functional biology rather than single markers.
Characterize target engagement as well as protein networks driving immune activation or suppression and therapeutic resistance mechanisms.
We’ve innovated our methods to enable oncology researchers to characterize the molecular landscape of tumors with significantly enhanced depth, breadth, and scale. These include:
SurfaceSeek™, SignalingSeek™, ImmuneSeek™, and ResistanceSeek™: a suite of mass spectrometry-based workflows to directly measure critical dimensions of functional tumor biology
Enabling protein-level characterization of druggable tumor cell surface targets, signaling pathway activation, immune biology, and resistance mechanisms – directly in human tumor tissue. See how.
DynamiQ is Sapient’s longitudinal molecular‑clinical data resource, built from tens of thousands of deeply phenotyped human samples. For oncology programs, DynamiQ enables:
Bridge the gap between inferred and functional biology to de-risk translation.
Layer your data and ours to orthogonally validate findings and extend discoveries.
Benefit from rapid access to clinically annotated FFPE tumors and tissues across common and rare diseases.
See how Sapient’s next-generation FFPE Proteomics method measures >10,000 proteins in a single FFPE tumor section, delivering protein- and pathway-level resolution across 200+ oncogenic pathways.
